Advair Generic: Mylan Takes Issue With US FDA's 'Major' Concerns
Executive Summary
Dispute over analysis of inhaler device could delay launch of competitor to GSK's franchise until 2018; FDA's complete response letter to Mylan' deemed 'major.'
You may also be interested in...
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.
US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs
Pre-ANDA meeting requests were high in some product categories where FDA conducted research projects, suggesting agency may influence sponsors' development priorities.